To drive expedient access to innovative healthcare solutions for the people of Hong Kong and Macau with high ethical standards.
Formed in 1968, The Hong Kong Association of the Pharmaceutical Industry has 33 full members, including the world’s top 20 companies engaged in the research and development of pharmaceuticals. Our member companies provide over 70 per cent of the prescription medicines in Hong Kong.
Updating members with important information in the local pharmaceutical market, the Association aims to improve the overall well-being of Hong Kong people by making recommendations on healthcare policies, as well as the relationship among our member companies, the government and the community.
The Association has actively participated in the events of the local health community and regularly presented its views to the public on different healthcare issues such as Voluntary Health Insurance Scheme, Pharmacy and Poisons (Amendment) Ordinance 2015 and various pharmaceutical regulations.
The Hong Kong Association of the Pharmaceutical Industry is one of the earliest associations in the world formed by R&D based pharma companies. Through these years, the Association has been working with different Bureaux and departments of the government, professional associations, academics and patients groups, consistently provided expert views across the entire spectrum of healthcare matters including healthcare system reform, research and development as well as patient empowerment.
HKAPI produced its first paper on healthcare reform in 1999. And over the years we have provided insight and commentary on a host of issues, including the Building a Healthy Tomorrow discussion paper, the Health Protection Scheme and the Voluntary Health Insurance scheme. In 2017, we presented a series of papers on primary healthcare, cancer strategy, and the affordability of drugs for rare diseases and cancer patients.In 2005, HKAPI provided the first position paper on the establishment of the Hospital Authority Drug Formulary, and the association continues to work with the HA to improve the access and affordability of medicines for patients in need.
To improve the standard of medical representation, in 1977, HKAPI launched a series of industry training programmes. In the 1980s, recognizing the need to further raise standards for ethical promotion and education by the industry, the HKAPI expanded the education courses and launched the first comprehensive series of Medical Representatives’ Training Programs for people and professional development. The HKAPI has been running these courses for 30 years.
Code of Practice
In 1970, HKAPI and its members adopted the first edition of the Code of Pharmaceutical Marketing Practices, developed in accordance with internationally defined standards. Code training workshops are held every year. Revised every two years, the 18th edition was rolled out in 2017. The Association’s implementation of the Code is a key pharmaceutical industry benchmark within the region, and HKAPI member companies are expected to adhere to it rigorously.